Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Repeat Insult Patch Test to Evaluate Personal Lubricants (HRIPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02737631
Recruitment Status : Completed
First Posted : April 14, 2016
Results First Posted : September 1, 2017
Last Update Posted : April 15, 2021
Sponsor:
Information provided by (Responsible Party):
Church & Dwight Company, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this test is to evaluate the sensitizing potential of a personal lubricant, as a result of repeated occlusive patch. The intervention will be applied for a total of 9 induction applications, followed by an approximately 2 week rest period, then followed by a 24-72 hour Challenge applications.

Condition or disease Intervention/treatment Phase
Erythema Edema Device: "Chameleon" Personal Lubricant Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 222 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: All participants receive the same interventions
Primary Purpose: Screening
Study Start Date : February 2016
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Healthy subject
Healthy subjects exposed to "Chameleon" personal lubricant via occlusive patch
 Device: "Chameleon" Personal Lubricant


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Patients That Showed Sensitization Reaction to the Test Material at Challenge [ Time Frame: 24, 48 and 72 hours after patch application ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • good health as determined from screener
  • signed and dated informed consent
  • signed and dated HIPAA Form

Exclusion Criteria:

  • subjects on test at any other research laboratory or clinic
  • known allergy or sensitivity to cosmetics and toiletries, including sunscreens, adhesives and/or topical drugs
  • pre-existing dermatologic conditions which have been diagnosed by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study
  • pre-existing other medical conditions (e.g. adult asthma, diabetes).
  • treatment with antibiotics, antihistamines or corticosteroids within two weeks prior to initiation of the test
  • chronic medication which could affect the results of the study (e.g., insulin, corticosteroids, antihistimines, steroidal or non-steroidal anti-inflammatory drugs [except for therapeutic maintenance dosage of aspirin], antibiotics, steroid inhalers, etc.)
  • known pregnant or nursing women
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737631


Locations
Layout table for location information
United States, New Jersey
Harrison Research Laboratories, Inc.
Union, New Jersey, United States, 07083
Sponsors and Collaborators
Church & Dwight Company, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Lynne B Harrison, PhD Harrison Research Laboratories, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Church & Dwight Company, Inc.
ClinicalTrials.gov Identifier: NCT02737631    
Other Study ID Numbers: ST-7619
First Posted: April 14, 2016    Key Record Dates
Results First Posted: September 1, 2017
Last Update Posted: April 15, 2021
Last Verified: March 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythema
Skin Diseases
Skin Manifestations